Lundbeck is so so unfair and doesn't have a clue on creating goals! Why not try by making the same increase for all - with a few exceptions??!!! The rankings are so wrong! Why is it ok for some people to have goals increased 95% and others got half that???????? Then those with the huge goals are ranked low - even though they may be cranking out much more than another rep with low goals!! So who gets ranked higher??? The one that did NOT do more or bring the company more money!!! WAKE UP HOME OFFICE! Adjust the goals to be FAIR for all!!!!!
Forget it sonny boy! We have adjusted the goals for you and we have more important things to do like Yammer JA
Marketing totally messed up. The betas are focused on trin because that's where the bonus bucks were the last trimesters. Therefore, we are under goal for Rex. as a nation. If they put the emphasis on Rex (percentage and bonus) it would guarantee Rex would be above 100%. Better yet, drop trin from our bag.
You just don't get it do you? They don't give a shit. The company is on track to exceed the $1 billion goal, but everyone I know is nowhere close to exceeding their own personal goal! This is by design. JA is more concerned with dumbass Yammer, which nobody gives a rat's ass about, than his sales team! No my friend, vote with your feet. That's the only answer.
Psych brings in no money, hence the goals. Onfi is the only thing keeping the lights on (and residual Xenazine). This house if cards is collapsing once the Ovation brands go generic.
Agreed. Trintellix and Rexulti still lose money. Its Onfi and Xenazine that make us $$$. The hope is that in another year or two, Trint & Rex will make enough $$ to offset the losses.
With the cut our partners get, it is virtually impossible to replace Onfi, Sabril, and Xenazine with our pathetic psych products. If idolapirdine doesn't get approved, 100% chance Lundbeck gets gutted by 2018.
It will be gutted likely earlier. Expect results by 1Q17 and if negative (which is likely given class and difficulty approval in that disease state)--it will be a blood bath in late to early fall of next yr. Rexulti really has very little differentiation to count on versus now a generic and cheaper Abilify. It's has marginal improvments many of which are theoretical. They are apparently was a head-to-head against Seroquel for Schizophrenia and it failed miserably and was beat resoundly by Seroquel and none of us AMs heard a peep. Takeda reps and marketing responsible for failed launch of Trintellix. That company does not understand CNS or Psych and led to mixed messages and increased nausea rates at launch. Tighten up the resumes peeps, it's gonna be a fun ride from here on out.
The first AD study results are now available to senior management. If that study fails, approval is near impossible. Read the tea leaves and be ready to run prior to the end of 16. Good luck to all.
Arena never even mentioned it in his video, just the drug for treatment resistant schizo. Wow! What a huge market that is! It's doubtful it will make it. We've got nothing in the pipeline, nothing. They have pissed off the salesforce with everything they do. Every time we turn around, somebody want to ride with us. Nothing new to talk about. 15 idiots with Otsuka and Takeda to deal with. There has got to be layoffs sometime in 2017.
